ALG-801 is a next-generation ligand trap targeting type IIA/IIB activin receptors that selectively sequesters a specific set of molecules that activate the Smad2/3 pathway, known to be involved in pulmonary arterial hypertension. Smad2/3 is implicated in the growth of pulmonary artery smooth muscle cells, which contributes to blood vessel remodeling, essentially structural alterations, and narrowing of pulmonary arteries. ALG-801 has successfully completed its Phase 1a and 1b clinical trials in healthy volunteers and is ready for Phase 2 clinical development.
Read more at this link on Pulmonary Hypertension News
Developer now planning Phase 2 trial to test therapy candidate